LIGAND PHARMA (LGDN.SG)
LIGAND PHARMA (LGDN.SG) operates in Diversified Metals & Mining.
LIGAND PHARMA (LGDN.SG) (LGDN) - Total Liabilities
Latest total liabilities as of September 2024: €113.69 Million EUR
Based on the latest financial reports, LIGAND PHARMA (LGDN.SG) (LGDN) has total liabilities worth €113.69 Million EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LIGAND PHARMA (LGDN.SG) - Total Liabilities Trend (2016–2023)
This chart illustrates how LIGAND PHARMA (LGDN.SG)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LIGAND PHARMA (LGDN.SG) Competitors by Total Liabilities
The table below lists competitors of LIGAND PHARMA (LGDN.SG) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KUEHNE+NAGEL INT N
MU:KNIA
|
Germany | €8.35 Billion |
|
The Singing Machine Company Inc. Common Stock
NASDAQ:MICS
|
USA | $13.24 Million |
|
Raise Production Inc
PINK:GLKFF
|
USA | $12.55 Million |
|
Haidemenos S.A.
AT:HAIDE
|
Greece | €14.64 Million |
|
Superior Industries International
NYSE:SUP
|
USA | $756.31 Million |
|
Kanani Industries Limited
NSE:KANANIIND
|
India | ₹287.50 Million |
|
Generation Income Properties Inc
NASDAQ:GIPR
|
USA | $74.52 Million |
|
Mathios Refractories S.A.
AT:MATHIO
|
Greece | €15.98 Million |
Liability Composition Analysis (2016–2023)
This chart breaks down LIGAND PHARMA (LGDN.SG)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LIGAND PHARMA (LGDN.SG)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LIGAND PHARMA (LGDN.SG) (2016–2023)
The table below shows the annual total liabilities of LIGAND PHARMA (LGDN.SG) from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €86.30 Million | -47.75% |
| 2022-12-31 | €165.18 Million | -65.33% |
| 2021-12-31 | €476.43 Million | -27.01% |
| 2020-12-31 | €652.76 Million | -10.30% |
| 2019-12-31 | €727.68 Million | +3.97% |
| 2018-12-31 | €699.89 Million | +158.04% |
| 2017-12-31 | €271.23 Million | +4.20% |
| 2016-12-31 | €260.30 Million | -- |